Pharma & Bio
Lifestyle
Choi Ho-jun, CEO of Wise birds Inc.: “We Will Lead the Way in Creating K-Bio Blockbusters”
South Korea’s pharmaceutical, biotech, and healthcare industries are accelerating their global expansion. Recently, products such as Zimpentra ( Celltrion(068270)) and Cenobamate ( SK BIOPHARMACEUTICA…
Lifestyle
GC Biopharma Corp.: Why Its Stock Price Is Falling Despite the Sale of Curevo… When Will It Start to Rise Again?
GCGreen Cross Corporation(006280)has continued its downward trend since announcing the sale of its stake in Curevo. Although the stock price has rebounded slightly over the past few days, analysts say…
Technology
The Unsung Heroes of K-Beauty: Aesthetic Clinics… Characteristics of Companies with High Profit Margins [Bio Series with Numbers, Part 4]
K-Aesthetics (cosmetic medicine) is at the heart of sectors where South Korea leads the global market. We have entered an era where the cash-generating power of a single wrinkle-smoothing injection or…
Technology
"From a Dream to 1000억 in Operating Profit"... The Keys to Strong Performance in New Drugs and Platforms [Bio: The Numbers Speak for Themselves ③]
“We’ve entered Phase 2 clinical trials,” “We’ve signed a contract with a global pharmaceutical company”Just a year ago, a single line like this was enough to double a biotech company’s stock price. Bu…
Lifestyle
GemVax & KAEL Co.,Ltd.: Expectations for Conditional Approval of Progressive Nuclear Paralysis Treatment… Preclinical Trials for ALS Also Show ‘Positive Signs’
GV1001, a new drug candidate from GemVax & KAEL Co.,Ltd.(082270)that is raising expectations for conditional approval in the field of progressive supranuclear palsy (PSP)—for which there are currently…
Business·Industry
'Taking on Legal Challenges Head-On': Shaperon Inc. Picks NezTech… 'Expanding into North America with Beauty DEVICES'
It has been known since last April that Shaperon Inc. ( Shaperon Inc.(378800)), a developer of new drugs for immune and inflammatory diseases, has been seeking merger and acquisition (M&A) targets. At…
Business·Industry
Macrogen, Inc. Transitions from Korea’s No. 1 NGS Provider to a Digital Healthcare Platform Company… ‘Profitability Remains a Challenge’
Macrogen, Inc.(038290)is pursuing a transformation from the leading company in South Korea’s next-generation sequencing (NGS) market to a digital healthcare platform company. The company plans to expa…
Lifestyle
[BioUSA] Moon Young-jun, Head of Business Development at NEUROPHET Inc.: “In Discussions for Additional Agreements with Roche and Lilly... Expecting to Turn a Profit Next Year”
At Bio USA, held in San Diego, U.S., global pharmaceutical companies are showing keen interest in imaging biomarker technology amid the expanding market for Alzheimer’s treatments. In particular, NEUR…
Lifestyle
Kim Nam-kyu, CEO of La Défense: “We’ve Left All Possibilities Open for OSCOTEC Inc., Including System Integration and Equity Participation”
“We are keeping all possibilities open, including attracting strategic investors (SIs) and equity participation. The key point is that this is not a hostile takeover aimed at short-term gains; rather,…
Lifestyle
EnSol Bio 'Loads Its Ammo,' Expanding Beyond Degenerative Diseases into Cancer and Brain Disorders
Ensol Biosciences (Ensol Bio), a leading player in the KONEX market, is expanding its reach beyond treatments for degenerative diseases into the fields of cancer and brain disorders. The company’s lar…